HanchorBio and InxMed Explore “Barrier Disruption + Myeloid Activation” Strategy for Difficult-to-Treat Solid Tumors

On July 8, 2026, FDB Biologics Limited, a subsidiary of HanchorBio, signed a strategic memorandum of understanding (MoU) with InxMed (Shanghai) Co., Ltd. At first glance, the announcement appears to be a preclinical and translational research collaboration. But scientifically, it asks a larger question that has become increasingly important in solid tumor drug development: can the physical barriers of the tumor microenvironment and the immune-suppressive myeloid system be addressed together?

The collaboration brings together HanchorBio’s HCB101, a clinical-stage SIRPα-Fc fusion protein targeting the CD47/SIRPα axis, with InxMed’s investigational tumor microenvironment-modulating assets, including the orally administered small-molecule focal adhesion kinase (FAK) inhibitor IN10018/ifebemtinib and the FAP-targeted antibody-drug conjugate OMTX705. The goal is to evaluate whether these complementary mechanisms may help address major therapeutic barriers in difficult-to-treat solid tumors, including stromal remodeling, extracellular matrix accumulation, tumor fibrosis, immune exclusion, and myeloid-mediated immunosuppression.

For HanchorBio, the collaboration also fits into a broader “anchor-and-expand” development logic for HCB101: establish clinical anchors in tumor settings where early signals are emerging, then evaluate whether the same macrophage-centered mechanism can be extended into other myeloid-rich, stroma-rich, or immune-excluded tumor ecosystems.

Why Difficult Solid Tumors Need More Than One Mechanism

Many hard-to-treat solid tumors are not protected by cancer cells alone. An ecosystem protects them. Dense stroma, activated fibroblasts, accumulated extracellular matrix, abnormal signaling pathways, and immune-suppressive myeloid cells can all restrict drug penetration, limit immune-cell access, and reduce the effectiveness of immunotherapy.

This is one reason why some tumors remain poorly responsive even when effective drug classes already exist. PD-1/PD-L1 inhibitors can release the brakes on T cells, but their activity may be limited when T cells are excluded from the tumor microenvironment or when upstream innate immune activation is insufficient. ADCs and targeted therapies may deliver potent payloads or pathway inhibition, but stromal and fibrotic barriers can still constrain their reach and durability.

In this context, the HanchorBio-InxMed collaboration is not simply a combination of assets. It is a test of a mechanistic hypothesis: if stromal and fibrotic tumor defenses can be modulated, can macrophage-centered immune activation become more effective in tumors that have historically resisted treatment?

Two Biological Angles: Myeloid Activation and Tumor Barrier Modulation

The collaboration brings together two different but potentially complementary approaches to solid tumor biology.

HCB101 targets the CD47/SIRPα pathway, widely known as the “don’t eat me” signal. Tumor cells can use CD47 to send inhibitory signals to macrophages through SIRPα, helping them evade phagocytosis. Blocking this pathway is intended to restore macrophage recognition and clearance of tumor cells.

The CD47 field, however, has been difficult. Earlier generations of CD47-targeting agents faced challenges related to hematologic toxicity, target sink, and insufficient therapeutic window. HCB101 was designed as a next-generation SIRPα-Fc fusion protein intended to block CD47/SIRPα signaling while supporting macrophage-mediated recognition and phagocytosis of tumor cells.

For HanchorBio, HCB101 is being positioned not only as a CD47/SIRPα blocker but as a macrophage-centered immunotherapy strategy. Because macrophages and other myeloid cells can shape antigen presentation, T-cell recruitment, and immune suppression within the tumor microenvironment, re-engaging macrophage activity may provide an upstream innate immune activation mechanism that can be combined with other therapeutic modalities.

InxMed contributes to the tumor barrier biology. Its lead asset, IN10018/ifebemtinib, is an investigational small-molecule FAK inhibitor. FAK signaling is involved in tumor survival, invasion, stromal remodeling, fibrosis, integrin signaling, and immune modulation, making it relevant to tumors where the surrounding microenvironment contributes to treatment resistance.

OMTX705 adds another dimension. As an ADC targeting fibroblast activation protein (FAP), it is designed to target fibroblast-rich tumor stroma. FAP biology is closely linked to cancer-associated fibroblasts and stromal architecture, both of which are central features of fibrotic and immune-excluded solid tumors.

Together, the collaboration creates a clear scientific premise: HCB101 is intended to activate macrophage-centered anti-tumor immunity, while InxMed’s investigational FAK- and FAP-directed programs are designed to explore stromal, fibrotic, and fibroblast-associated tumor barriers.

InxMed: Targeting Tumor Defense Through FAK and FAP Biology

InxMed has built its pipeline around cancer drug resistance and tumor defense mechanisms. Its lead asset, IN10018/ifebemtinib, is an investigational small-molecule FAK inhibitor. FAK signaling is involved in tumor survival, invasion, stromal remodeling, fibrosis, integrin signaling, and immune modulation, making it highly relevant to tumors, where the microenvironment contributes to treatment resistance.

InxMed has advanced IN10018/ifebemtinib into late-stage clinical development, including a Phase III trial in China for platinum-resistant recurrent ovarian cancer, and the program has received Fast Track designation from the U.S. FDA. While it is not a standard-of-care backbone, it is a clinically advanced investigational asset with a clear rationale for targeting the tumor microenvironment.

OMTX705 adds another dimension to the collaboration. As a FAP-targeted ADC, it is designed to target fibroblast-rich tumor stroma. FAP biology is closely linked to cancer-associated fibroblasts and stromal architecture, both of which are central features of fibrotic and immune-excluded tumors. In this collaboration, OMTX705 serves as a means to explore whether fibroblast- and stroma-directed targeting can complement macrophage-centered immune activation.

The Combination Logic: Barrier Disruption Plus Myeloid Activation

The scientific logic of the collaboration can be summarized in one phrase: barrier disruption plus myeloid activation.

InxMed’s assets bring investigational approaches to modulating stromal, fibrotic, and fibroblast-driven barriers. HCB101 brings a macrophage-centered immune activation strategy through CD47/SIRPα blockade. Together, the collaboration will evaluate whether these mechanisms can generate a more favorable tumor microenvironment for anti-tumor immunity.

This is particularly relevant for difficult tumor settings where fibrosis, stromal density, immune exclusion, and myeloid suppression overlap. Examples may include pancreatic cancer, cholangiocarcinoma, diffuse-type gastric cancer, liver cancer, and other solid tumors with strong stromal or myeloid features. These tumors often remain challenging for existing immunotherapies and represent high unmet medical needs.

Importantly, the collaboration remains at the preclinical and translational research stage. Its purpose is not to claim clinical synergy today, but to generate mechanistic and translational insights that may guide future development decisions.

Clinical Data Highlight Why the Combination Strategy Is Biologically Plausible

The rationale for the HanchorBio-InxMed collaboration is supported by emerging clinical and translational evidence from both companies. Rather than pairing HCB101 with a conventional standard-of-care backbone, the collaboration is designed to test whether macrophage-centered immune activation can be combined with investigational approaches that modulate the fibrotic and stromal tumor microenvironment.

As the innate immune anchor in HanchorBio’s combination strategy, HCB101 has recently generated clinical signals across multiple solid tumor settings, with data presented at major international oncology meetings, including ASCO 2026 and JCA-AACR. In second-line gastric/gastroesophageal junction (GEJ) cancer, HCB101 in combination with ramucirumab and paclitaxel reported an overall objective response rate (ORR) of 57.1% and an ORR of 80% in mature mid-dose cohorts, with deep tumor regressions up to 78.2% and ongoing responses beyond 34 weeks. 

Beyond gastric cancer, HCB101 has also shown activity in tumor settings where macrophage biology and myeloid-mediated immune suppression may play an important role. In head and neck cancer, HCB101 monotherapy achieved durable tumor shrinkage of over 40% with effects lasting over 74 weeks. In addition, researchers observed cases of durable antitumor activity in PD-1-naïve patients resulting in complete response (CR), partial response, and disease stabilization at low-dose HCB101 combination therapy with PD-1/PD-L1 inhibitor. Additional signals presented at ASCO 2026 included activity in first-line HER2-positive gastric cancer, first-line triple-negative breast cancer, and a first confirmed partial response in the colorectal cancer cohort of its ongoing HCB101-201 combination study, supporting the company’s strategy to evaluate HCB101 across selected myeloid-rich solid tumors.

On the InxMed side, IN10018/ifebemtinib is a highly selective, orally administered FAK inhibitor targeting focal adhesion kinase, a pathway involved in tumor survival, stromal remodeling, invasion, drug resistance, and immune modulation. InxMed’s public materials describe IN10018/ifebemtinib as a clinical-stage FAK inhibitor being evaluated across multiple tumor types and combination settings. 

InxMed has also reported clinical progress for IN10018/ifebemtinib-based combinations. In platinum-resistant ovarian cancer, the regimen in combination with pegylated liposomal doxorubicin (PLD) achieved an ORR of 40.7%, a disease control rate (DCR) of 81.5%, and a significant improvement in overall survival. IN10018/ifebemtinib received Fast Track Designation from the U.S. FDA, supporting its continued development in high-unmet-need settings. In KRAS G12C-mutant non-small cell lung cancer (NSCLC), InxMed reported Phase Ib/II data showing high response rates when IN10018/ifebemtinib was combined with the KRAS G12C inhibitor, garsorasib, including an ORR of 90.3%, DCR of 96.8%, and an estimated median progression-free survival (mPFS) of 22.3 months in a previously reported NSCLC cohort.

The second InxMed asset, OMTX705, adds another angle to the tumor microenvironment. OMTX705 is a FAP-targeted antibody-drug conjugate (ADC) targeting fibroblast activation protein alpha, which is highly expressed in cancer-associated fibroblasts surrounding tumor cells and tumor vasculature. InxMed has publicly described OMTX705 as an ADC intended to address FAP-positive tumor-stromal biology and tumor drug resistance. Clinical and translational data presented at ASCO 2025 further suggested that OMTX705 may modulate CAF-mediated immunosuppression, with immune cell infiltration and cytokine changes observed in selected patient samples.  

Together, these data provide the scientific foundation for the collaboration: HCB101 brings a macrophage-centered immune activation strategy, while InxMed contributes investigational approaches targeting FAK- and FAP-associated tumor defense mechanisms. The central question now is whether these mechanisms can be combined to address the stromal, fibrotic, and immunosuppressive barriers that make many solid tumors difficult to treat.

Clinical Anchors Create an Expansion Logic for HCB101

These data help explain HanchorBio’s broader anchor-and-expand strategy for HCB101.

Rather than treating HCB101 as a single-indication asset, HanchorBio is using gastric cancer as a defined clinical anchor while exploring whether its macrophage-centered mechanism can be extended into biologically selected tumor settings.

The InxMed collaboration adds another dimension to this strategy. It asks whether HCB101’s myeloid-enhancing mechanism can be paired with investigational approaches that address stromal and fibrotic barriers — features common in some of the most difficult-to-treat solid tumors.

This is where HCB101’s development logic moves from clinical anchor to biology-guided expansion: first establish activity in defined tumor settings, then test portability across myeloid-enriched, stroma-rich, or immune-excluded tumor ecosystems.

Management Perspectives

 “HCB101 has demonstrated encouraging potential as a macrophage-centered immunotherapy strategy across myeloid-rich tumor settings,” said Zaiqi Wang, MD, PhD, Founder, Chairman, and CEO of InxMed. “InxMed is committed to overcoming cancer drug resistance, and our lead asset, IN10018/ifebemtinib has entered late-stage clinical development, including Phase III clinical trials in Mainland China for platinum-resistant recurrent ovarian cancer, and has received Fast Track Designation from the U.S. FDA. We believe this collaboration may create a complementary therapeutic synergy for highly fibrotic and treatment-resistant tumor microenvironments.”

Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio, noted that the collaboration may deepen the understanding of HCB101’s mechanism of action across diverse tumor microenvironments and provide a research foundation for potential expansion into stroma-rich, immune-excluded, or myeloid-enriched solid tumors, such as pancreatic cancer, cholangiocarcinoma, and diffuse-type gastric cancer.

“Through this collaboration, we aim to evaluate HCB101’s potential to block the CD47/SIRPα signaling axis and enhance macrophage-mediated recognition and phagocytosis of tumor cells, while combining it with IN10018/ifebemtinib and OMTX705 to address tumor fibrosis, stromal barriers, and immunosuppressive features of difficult-to-treat solid tumors from different mechanistic angles,” Dr. Liu said.

From MOU to Translation Readout

The next step for HanchorBio and InxMed will be to review preclinical and translational research findings and determine potential next steps. For a research-stage MOU, the most important near-term output will not be a clinical commitment, but evidence that the combination hypothesis is biologically sound.

Key questions may include whether stromal or fibroblast-directed modulation changes immune-cell infiltration, whether macrophage-mediated phagocytosis is enhanced in fibrotic tumor models, whether the combination shifts immune exclusion toward immune engagement, and whether safety or dosing considerations support further development planning.

If the collaboration generates supportive translational data, it could help HanchorBio refine the positioning of HCB101 as a macrophage-centered immunotherapy backbone and provide a stronger rationale for expanding beyond current clinical anchors into more difficult tumor ecosystems.

In that sense, the HanchorBio-InxMed MOU is not merely a partnership announcement. It is a carefully defined scientific test: can a tumor’s physical defenses and immune-suppressive myeloid biology be addressed together to open a new path for difficult-to-treat solid tumors?

Author

Richard Chau